101 related articles for article (PubMed ID: 6396596)
1. Investigation of biotransformation capacity in patients with chronic liver diseases by pharmacokinetic methods: experimental trials.
Horváth T; Past T; Tatai Z; Pár A; Kádas I; Tapsonyi Z; Jávor T
Pol J Pharmacol Pharm; 1984; 36(4):361-71. PubMed ID: 6396596
[TBL] [Abstract][Full Text] [Related]
2. Disorders of biotransformation during the progression of alcoholic liver disease.
Horváth T; Pár A; Past T; Beró T; Tapsonyi Z; Kádas I
Acta Med Hung; 1986; 43(4):351-7. PubMed ID: 3601579
[TBL] [Abstract][Full Text] [Related]
3. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
[TBL] [Abstract][Full Text] [Related]
5. Sulfadimidine kinetics in patients with various chronic liver diseases.
Horváth T; Past T; Par A; Kádas I; Jávor T
Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
[TBL] [Abstract][Full Text] [Related]
6. Drug metabolism in alcoholic liver disease.
Horváth T; Pár A; Past T; Tapsonyi Z; Ruzsa C; Kádas I; Jávor T
Acta Med Acad Sci Hung; 1982; 39(3-4):169-77. PubMed ID: 7185242
[No Abstract] [Full Text] [Related]
7. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
Traeger A; Horváth T; Rechenbach C; Jávor T
Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
[TBL] [Abstract][Full Text] [Related]
8. Sulfadimidine and isoniazid loading in man and laboratory rats. Pharmacokinetic and pharmacogenetic results on drug acetylation.
Dubbels R; Kattner E; Sell-Maurer D; Schloot W
Arzneimittelforschung; 1980; 30(9):1574-9. PubMed ID: 7193028
[TBL] [Abstract][Full Text] [Related]
9. Impairment of drug elimination in patients with liver disease.
Narang AP; Datta DV; Mathur VS
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Ohnhaus EE; Münch U; Meier J
Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
[TBL] [Abstract][Full Text] [Related]
11. Effect of alphamethyldopa on the half-lives of antipyrine, tolbutamide and D-glucaric acid excretion in man.
Gachályi B; Tornyossy M; Vas A; Káldor A
Int J Clin Pharmacol Ther Toxicol; 1980 Mar; 18(3):133-5. PubMed ID: 6103880
[TBL] [Abstract][Full Text] [Related]
12. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
Chauhan CK; Nanivadekar SA; Billimoria FR
Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
[TBL] [Abstract][Full Text] [Related]
13. [Simultaneous administration of various model substances for characterizing in vivo biotransformation in chronic liver diseases].
Truckenbrodt J; Kraul H; Huster A; Töpfer R; Henschel L; Hoffmann A; Reinhardt M; Jorke D
Gastroenterol J; 1990; 50(4):179-82. PubMed ID: 2091673
[TBL] [Abstract][Full Text] [Related]
14. [Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency].
Kettner W; Banditt P; Walther H
Dtsch Z Verdau Stoffwechselkr; 1983; 43(6):255-66. PubMed ID: 6662064
[TBL] [Abstract][Full Text] [Related]
15. Antipyrine pharmacokinetics and D-glucaric excretion in kwashiorkor.
Buchanan N; Eyberg C; Davis MD
Am J Clin Nutr; 1979 Dec; 32(12):2439-42. PubMed ID: 506967
[TBL] [Abstract][Full Text] [Related]
16. [Aminophenazone half life in patients with chronic liver parenchyma disorders].
Ackermann E; Renger F; Dökert B; Walther M
Z Gesamte Inn Med; 1972 Oct; 27(19):849-53. PubMed ID: 4647370
[No Abstract] [Full Text] [Related]
17. [Drug metabolism in patients with liver disease (author's transl)].
Richter E; Epping J; Fuchshofen-Röckel M; Heusler H; Zilly W
Leber Magen Darm; 1980 Oct; 10(5):234-40. PubMed ID: 7464410
[TBL] [Abstract][Full Text] [Related]
18. Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Farrell GC; Cooksley WG; Hart P; Powell LW
Gastroenterology; 1978 Oct; 75(4):580-8. PubMed ID: 710827
[TBL] [Abstract][Full Text] [Related]
19. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
[TBL] [Abstract][Full Text] [Related]
20. Human tolerance of flumecinol (Zixoryn, RGH-3332), its regime and dosage in healthy volunteers.
Vezekenyi Z; Ferenci J; Radnai B; Horvath T; Past T; Nagy L; Jávor T
Int J Clin Pharmacol Res; 1983; 3(2):77-88. PubMed ID: 6679516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
